Document ID: chunk:federal_register_of_legislation:F2024N01149:schedule:1:p5
Version: federal_register_of_legislation:F2024N01149
Segment Type: schedule
Provision Reference: sch 1 (pt 5/6)
Character Range: 20796–25369

benefit; and
                (f)                  specified duration or indication that medicine is to be supplied for duration of chart; and
                (g)                 brand substitution indicator; and
                (h)                 Authority Prescription Number; and
                (i)                  Closing the Gap (CTG); and
                (j)                  PBS/RPBS; and
                (k)                 Streamlined Authority; and
                (l)                  additional instructions (if any) to be added by the medical practitioner, expressed as' Additional Instructions'.
            11.2            Information requirements for a pharmaceutical benefit other than insulin, that is required to be administered at a variable dose must also include a record of each administration of the benefit with the following details:
                (a)                 pharmaceutical benefit; and
                (b)                 form; and
                (c)                 strength; and
                (d)                 dose; and
                (e)                 route; and
                (f)                  date and time; and
                (g)                 dose administered; and
                (h)                 credentials of the first nurse authorising and administering the pharmaceutical benefit; and
                (i)                  credentials of the second nurse authorising and administering the pharmaceutical benefit.

      12.  Infusion and Transdermal Patch pharmaceutical benefit additional requirements

            12.1            The additional information requirements for prescribing of a pharmaceutical benefit that is an infusion or transdermal patch must include additional instructions to be added by the medical practitioner, expressed as 'Additional Instructions' to capture information of the pharmaceutical benefit, such as:
                (a)                 infusion instructions; and
                (b)                 infusion liquid; and
                (c)                 rate/time; and
                (d)                 maximum hourly rate; and
                (e)                 daily limits.
            12.2            The additional information requirements for prescribing of a pharmaceutical benefit that is a Transdermal Patch must include additional instructions to be added by the medical practitioner, expressed as 'Additional Instructions' to capture information of the pharmaceutical benefit, such as:
                (a)                 day for application; and
                (b)                 instructions for safe removal; and
                (c)                 placement of patch; and
                (d)                 minimum 'patch free' time.

      13.   Schedule 8 (controlled) pharmaceutical benefits additional requirements

            13.1            The additional information requirements for prescribing and administration of a Schedule 8 (controlled) pharmaceutical benefit must include the following:
                (a)                 credentials of the second nurse authorising and administering the pharmaceutical benefit; and
                (b)                 sedation scores; and
                (c)                 functional assessment.

      14.  Nutritional supplements pharmaceutical benefits

            14.1            The information requirements for a pharmaceutical benefit that is a nutritional supplement must include the following:
                (a)                 particulars sufficient to identify the pharmaceutical benefit, including the name and strength, expressed as 'nutritional supplement'; and
                (b)                 the pharmaceutical benefit's:
                    (i)                  date of prescribing; and
                    (ii)                dose; and
                    (iii)              route of administration; and
                    (iv)              frequency of administration; and
                    (v)                 Indication for use (when relevant); and
                (c)                 the day, month and year of the date (the start date) to start administering the pharmaceutical benefit; and
                (d)                 the day, month and year of the date (the stop date) to stop administering the pharmaceutical benefit; and
                (e)                 specified duration or indication that medicine is to be supplied for duration of chart; and
                (f)                  brand substitution indicator; and
                (g)